Efficacy and safety of resveratrol, an oral hemoglobin F-augmenting agent, in patients with beta-thalassemia intermedia.

摘要: Recently, resveratrol showed induction of γ-globin mRNA synthesis in human erythroid precursors and reducing oxidative stress red cells thalassemia patients many vitro studies. We aimed to investigate the efficacy safety resveratrol, for first time, non-transfusion-dependent beta-thalassemia intermedia (B-TI) Southern Iran. In this double-blind randomized clinical trial, 54 with B-TI were investigated during 6 months between October 2016 March 2017. Patients randomly allocated into three groups by simple randomization method. Group 1 (hydroxyurea (HU) placebo, 18 patients), group 2 (resveratrol/piperine 16 3(HU resveratrol/piperine, 20 patients). Primary end point was considered as change hemoglobin (Hb) levels need blood transfusion. Drug a secondary point. Mean age 28.2 ± 5.6 (18-42) years. Response rate not significantly different among (P > 0.05). Higher percentages adverse events detected (31.3%) 3 (25%) compared (5.6%). However, difference statistically significant All reported gastrointestinal symptoms. Resveratrol similar HU small population non-transfusion 6-month follow-up. Complications, mostly gastrointestinal, observed more frequently group. Although it significant, attention should be given an oral HbF-augmenting agent.